Sensei Biotherapeutics to Participate in Citi’s 2022 Virtual Immuno-Oncology Summit

Rhea-AI Summary

BOSTON, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics (NASDAQ: SNSE) announced its participation in Citi's 2022 Immuno-Oncology Summit. Dr. Robert Pierce, Chief R&D Officer, will engage in a fireside chat on February 16, 2022, at 2:30 PM ET. The event will be webcast live, with a replay available for 90 days on the company's website. Sensei Biotherapeutics specializes in next-generation immunotherapies for cancer, utilizing its TMAb™ platform for antibody development and ImmunoPhage™ platform to create personalized treatments for various cancers.

BOSTON, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that company management will participate in Citi's 2022 Immuno-Oncology Summit.

Dr. Robert Pierce, Chief R&D Officer, will participate in a fireside chat beginning at 2:30pm ET on Wednesday, February 16, 2022. A webcast of the fireside chat will be available on the Events & Presentations section of Sensei’s website at www.senseibio.com. A replay of the webcast will be on the website for approximately 90 days following the event.

About Sensei Biotherapeutics
Sensei Biotherapeutics is a biopharmaceutical company engaged in discovery, development, and delivery of next generation immunotherapies with an initial focus on treatments for cancer. Sensei has developed two unique approaches – its TMAb™ (Tumor Microenvironment Activated biologics) platform, comprising unique human monoclonal antibodies and alpaca derived nanobodies that are selectively active in the tumor microenvironment, and its ImmunoPhage™ platform that leverages bacteriophage to drive the generation of tumor antigen-specific immune responses. Using its TMAb platform, the company has developed SNS-101, an antibody-based therapeutic targeting an immune checkpoint gene that inhibits anti-tumor immune responses called V-domain Ig suppressor of T cell activation (VISTA). Using the ImmunoPhage platform, Sensei is developing a library of ImmunoPhage, called Phortress™, with multiple tumor-associated antigens to create a personalized, yet off-the-shelf cocktail approach for treating cancer patients. The platform is designed to enable efficient, scalable and cost-effective manufacturing to support all of Sensei’s clinical programs. SNS-401-NG is an ImmunoPhage cocktail in preclinical development for the treatment of Merkel Cell Carcinoma. For more information, please visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn.

Investor Contact:
Erin Colgan
Chief Financial Officer
Sensei Biotherapeutics
ecolgan@senseibio.com

FAQ

When is Sensei Biotherapeutics participating in the Immuno-Oncology Summit?

Sensei Biotherapeutics will participate in Citi's 2022 Immuno-Oncology Summit on February 16, 2022.

Who from Sensei Biotherapeutics will speak at the summit?

Dr. Robert Pierce, Chief R&D Officer, will participate in a fireside chat at the summit.

What time is the fireside chat at the Immuno-Oncology Summit?

The fireside chat will begin at 2:30 PM ET on February 16, 2022.

Where can I watch the webcast of the fireside chat?

The webcast will be available on Sensei Biotherapeutics' website in the Events & Presentations section.

What is the focus of Sensei Biotherapeutics?

Sensei Biotherapeutics focuses on the discovery and development of next-generation immunotherapies for cancer.

What platforms does Sensei Biotherapeutics use for developing therapies?

Sensei uses the TMAb™ platform for antibody-based therapeutics and the ImmunoPhage™ platform for personalized treatments.